<- Go Home
Histogenics Corporation
As of September 27, 2019, Histogenics Corporation was acquired by Ocugen, Inc., in a reverse merger transaction. Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.
Market Cap
$4.5M
Volume
114.0K
Cash and Equivalents
$2.8M
EBITDA
-$19.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$85.80
52 Week Low
$1.95
Dividend
N/A
Price / Book Value
-0.51
Price / Earnings
-0.13
Price / Tangible Book Value
-0.51
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$20.0M
Return on Equity
16.69%
Return on Assets
-136.46
Cash and Short Term Investments
$2.8M
Debt
N/A
Equity
-$8.7M
Revenue
N/A
Unlevered FCF
-$21.0M
Sector
Biotechnology
Category
N/A